OSM and sIL-6Rα do not predict survival in pediatric AML samples. For a subset of patients with available samples, levels of OSM and sIL-6Rα were evaluated. For OSM, levels between diagnostic AML BM plasma samples and normal controls differed significantly (A), though there was no difference between levels at diagnosis vs remission in a paired sample analysis (B). No cut point was identified that predicted outcome for OSM level (cut point of 50 pg/mL is shown in panel C). sIL-6Rα BM plasma levels were not significantly different between normal controls and AML samples at diagnosis (D) or between diagnostic and remission samples in a paired sample analysis (E). *P < .05; ns, not significant.